Evidence map›Paper›PMID 42283826›Full record

SynthesisCancer chemotherapy and pharmacology2026

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Myriam Briki, Paul Thoueille, Markus Joerger, Etienne Chatelut, Marylise Sterle, Antonin Schmitt, Anna Dorothea Wagner, Thierry Buclin, Sandro Carrara, Monia Guidi

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Myriam BrikiService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. myriam.briki@epfl.ch.ORCID http://orcid.org/0000-0001-6334-5565
Paul ThoueilleService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-2305-4277
Markus JoergerDepartment of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.ORCID http://orcid.org/0000-0001-6602-6287
Etienne ChatelutIUCT-Oncopole, University of Toulouse, Oncopole Claudius Regaud, Toulouse, INSERM UMR1037, France.ORCID http://orcid.org/0000-0002-7740-9096
Marylise SterleUniversité Bourgogne Europe, Centre Georges-François Leclerc, Service Pharmacie, INSERM, CTM UMR 1231, TiRECs/STARTER-BFC, Dijon, France.ORCID http://orcid.org/0009-0000-0645-8934
Antonin SchmittUniversité Bourgogne Europe, Centre Georges-François Leclerc, Service Pharmacie, INSERM, CTM UMR 1231, TiRECs/STARTER-BFC, Dijon, France.ORCID http://orcid.org/0000-0002-3132-7730
Anna Dorothea WagnerDepartment of Oncology, Division of Medical Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-4728-7013
Thierry BuclinService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0639-5536
Sandro CarraraBio/CMOS Interfaces Laboratory, Department of Engineering, Swiss Federal Institute of Technology in Lausanne - EPFL, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0404-7917
Monia GuidiService of Clinical Pharmacology, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-6419-9317

Funding

Swiss National Science Foundation 200021_207900/1
6 · The paper itself

Abstract

purposeThe pharmacokinetics (PK) of 5-fluorouracil (5-FU) has been thoroughly studied over the past decades. Using an individual patient data model-based meta-analysis (IPD-MBMA) approach, this study aims to build a generalized model by combining IPD from multiple studies, investigating the role of lean body mass (LBM) in 5-FU PK, and exploring a model informed precision dosing (MIPD)-based approach for refining its therapeutic drug monitoring (TDM).

methodsRaw PK data from three 5-FU PK studies (726 patients, 2,332 plasma concentrations) were harmonized and grouped into one homogeneous dataset, preserving traceability to the original data source. An overall population PK (popPK) model for intravenous 5-FU was developed using nonlinear mixed-effects modeling (NONMEM).

resultsA two-compartment model with both saturable (Michaelis-Menten elimination; V

conclusionAggregating IPD enables building more generalizable popPK models while accommodating study-specific residual variability; broader raw-data sharing would strengthen current evidence and reveal remaining gaps. For 5-FU, BSA dosing leaves substantial interpatient variability, so LBM-based and model-informed strategies, including a priori dosing and MIPD-assisted TDM, warrant prospective evaluation.

Indexed as

Antimetabolites, AntineoplasticFluorouracilModels, BiologicalAdministration, IntravenousAgedBody Surface AreaDrug MonitoringFemaleHumansMaleMiddle AgedAntimetabolites, AntineoplasticFluorouracilFluorouracilModel-informed precision dosingOncologyPersonalised carePharmacokineticsTherapeutic drug monitoring

Identifiers

PMID42283826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.